Navigation Links
Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs
Date:11/4/2010

treated metastatic gastric cancer patients 128

SWOT analysis 128

Datamonitor drug assessment scorecard for Afinitor 129

Clinical and commercial attractiveness 130

If Phase III trial replicates Phase II survival, then Afinitor could become the standard of care in second-line metastatic gastric cancer 130

A relatively high rate of treatment discontinuation due to adverse events was seen in the Phase II study 130

Afinitor is set to be the first agent to reach the market for second-line metastatic gastric cancer 131

Afinitor shows applicability for use across the wider gastric cancer population 131

Design of the Phase III GRANITE-1 study may unnecessarily come under fire 131

Novartis's experience in the oncology market will prove crucial in ensuring Afinitor's success in gastric cancer 131

Satisfaction of unmet needs 131

Forecasts to 2019 132

Tykerb (lapatinib; GlaxoSmithKline) 133

Drug overview 133

Drug profile 133

Key historical events 134

Clinical trial data 135

Phase II results have shown minimal activity in first-line metastatic gastric cancer and failure to meet its primary endpoint of overall response rate 136

SWOT analysis 136

Datamonitor drug assessment scorecard for Tykerb 137

Clinical and commercial attractiveness 138

Minimal clinical data have been reported for Tykerb in gastric cancer, making it difficult to judge its clinical attractiveness 138

Dual inhibition of EGFR and HER-2 is a relatively new strategy in treatment of gastric cancer 139

Concerns exist over Tykerb's association with hepatotoxicity 139

Tykerb could provide strong competition to Herceptin in HER-2-positive gastric cancer 139

Satisfaction of unmet needs 139

Forecasts to 2019 140

Ramucirumab (IMC-1121B; Eli Lilly) 141

Drug overview 141

Drug profile 141

Key historical events 142

'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
2. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
4. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
5. Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports
6. Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
7. Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
8. Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
9. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
10. Reportlinker Adds Interventional Cardiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
11. Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Leading events organizer UBM Live announces that ... year to São Paulo, Brazil from ... event will co-locate with Food Ingredients South America (FiSA), creating ... for the pharmaceutical industry.      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... are now exploring the South America ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... 19, 2007 - Acorda,Therapeutics (Nasdaq: ACOR) today announced ... Center at the University,of Rochester, will present data ... in multiple sclerosis at the,upcoming American Academy of ... on Wednesday May 2, 2007 at 4:15 pm,Eastern ...
... Full Study Results,to Be Presented at the American ... ,WIRE) -- 03/19/2007 -- AtheroGenics, Inc. (NASDAQ: AGIX) ... of its lead drug,candidate, AGI-1067, did not show ... however, it did achieve a number of,other important ...
Cached Medicine Technology:Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting 2AtheroGenics Reports ARISE Trial Results for AGI-1067 2AtheroGenics Reports ARISE Trial Results for AGI-1067 3AtheroGenics Reports ARISE Trial Results for AGI-1067 4
(Date:7/25/2014)... July 26, 2014 2014 Deep ... Confocal Microscope Industry” is a professional and ... Confocal Microscope market. The report provides basic ... Scanning Confocal Microscope definition, classification, application, and ... This research covers international market analysis, including China’s ...
(Date:7/25/2014)... 25, 2014 American motor vehicle owners ... collisions can pay higher premiums for vehicle insurance on ... insurer network to provide SR22 insurance for high risk ... The different coverage network of local agencies providing direct ... search platform now publicly available for any car owner ...
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... of Dangerous Synthetic Marijuana Increasing (7/3), the state of ... synthetic marijuana, more so even than cocaine. Officials believe the ... safe because it's a “form” of marijuana. However, both doctors ... truth. Going so far as to call it “poison,” doctors ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Seniors are ... younger people, a new study finds. "Almost any ... memory from the age of 25 on," study co-author ... in a university news release. However, Martin said, ... impact on processing in older adults compared with younger ...
(Date:7/25/2014)... As reported by Wood TV 8 in ... Michigan has seen a nearly 500-person increase in heroin related ... was 271 between 1999 and 2002, the toll increased to ... like other states, drug users in Michigan have turned to ... He compared the price of both substances, noting that an ...
Breaking Medicine News(10 mins):Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Distractions Seem More Troublesome With Age 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2
... executives who have almost 50 years of hospital negotiating experience. Our ... a focus of expertise to help buyers become even more effective. ... all hospital purchases. There is finally help. , ... ...
... rituximab causes considerable kidney injury healing in patients with ... to a study appearing in the November 2008 issue ... Nephrology (CJASN) . The results suggest that this condition, ... percent of cases, can actually be healed in some ...
... Ill., Aug. 5 Healthation CEO Scott Kornhauser,announced ... Services. Collins brings to Healthation more than 20 ... include Vice President of Professional Services of,Aptiv Technology ... will be focused on leading, recruiting, and managing ...
... of Princeton psychology researchers has developed a computer program ... what it is about certain human faces that makes ... they have also found that the program allows them ... or dominant faces possible. , Such work could have ...
... carts from Eagle MHC are designed for maximum cleanability and sterile ... ... -- http://www.eaglegrp.com/ [Steril-Eze® surgical case carts] from Eagle MHC ... product line - which encompasses a wide range of choices in ...
... (NPF) announced it will fund $3.7 million in ... outreach worldwide.,Grants were awarded to institutions in the ... care centers, and 10 outreach,centers. Through centers alone, ... and almost 70,000 patients with movement disorders., ...
Cached Medicine News:Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 2Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 3Health News:Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease 2Health News:Whom do we fear or trust? 2Health News:Whom do we fear or trust? 3Health News:New Steril-Eze Surgical Case Carts from Eagle MHC Feature Rugged, Easy-Clean Design 2Health News:National Parkinson Foundation Awards $3.7 Million in Grants 2
... and Only 16-Electrode Non-Rechargeable ... of RESTORE with the convenience of ... unrivaled RESTOREPRIME. The ultimate non-rechargeable device, ... managing patients with bilateral and complex ...
... a rechargeable neurostimulator equipped with a battery ... a 9-year FDA approved battery life. It ... market. This is helpful to people who ... What makes RESTOREADVANCED and PRIMEADVANCED different from ...
... is an acellular dermal matrix derived from ... AATB-compliant tissue banks utilizing the standards of ... and Food and Drug Administration's (FDA) guidelines. ... and not significantly changed in structure from ...
... a modular external fixation system designed to ... clinical needs. Originally marketed in Europe under ... 20 year history of clinical use in ... principles of the Ilizarov technique begun in ...
Medicine Products: